Business Description
CytomX Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US23284F1057
Description
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.1 | |||||
| Equity-to-Asset | -0.17 | |||||
| Debt-to-Equity | -0.45 | |||||
| Debt-to-EBITDA | 1.24 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -5.5 | |||||
| Beneish M-Score | 1.47 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -2.6 | |||||
| 3-Year EBITDA Growth Rate | 67.5 | |||||
| 3-Year EPS without NRI Growth Rate | 80.7 | |||||
| 3-Year Book Growth Rate | -63.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -362.23 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -31.02 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.66 | |||||
| 9-Day RSI | 49.99 | |||||
| 14-Day RSI | 51.85 | |||||
| 3-1 Month Momentum % | -17.05 | |||||
| 6-1 Month Momentum % | -30.72 | |||||
| 12-1 Month Momentum % | -26.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.04 | |||||
| Quick Ratio | 1.04 | |||||
| Cash Ratio | 0.99 | |||||
| Days Sales Outstanding | 14.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.7 | |||||
| Shareholder Yield % | 4.62 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 5.3 | |||||
| Net Margin % | 10.92 | |||||
| FCF Margin % | -70.17 | |||||
| ROE % | Neg. Equity | |||||
| ROA % | 7.63 | |||||
| ROIC % | 4.33 | |||||
| 3-Year ROIIC % | 88.93 | |||||
| ROC (Joel Greenblatt) % | 45.4 | |||||
| ROCE % | 17.07 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 6.94 | |||||
| Forward PE Ratio | 12.75 | |||||
| PE Ratio without NRI | 6.94 | |||||
| PEG Ratio | 0.16 | |||||
| PS Ratio | 0.78 | |||||
| EV-to-EBIT | -2.89 | |||||
| EV-to-EBITDA | -2.26 | |||||
| EV-to-Revenue | -0.16 | |||||
| EV-to-Forward-Revenue | 0.02 | |||||
| EV-to-FCF | 0.16 | |||||
| Price-to-GF-Value | 0.39 | |||||
| Earnings Yield (Greenblatt) % | -34.65 | |||||
| FCF Yield % | -101.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CytomX Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 115.999 | ||
| EPS (TTM) (€) | 0.154 | ||
| Beta | 0.62 | ||
| 3-Year Sharpe Ratio | -0.38 | ||
| 3-Year Sortino Ratio | -0.58 | ||
| Volatility % | 88.56 | ||
| 14-Day RSI | 51.85 | ||
| 14-Day ATR (€) | 0.064895 | ||
| 20-Day SMA (€) | 0.982375 | ||
| 12-1 Month Momentum % | -26.49 | ||
| 52-Week Range (€) | 0.7955 - 4.438 | ||
| Shares Outstanding (Mil) | 78.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CytomX Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CytomX Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
CytomX Therapeutics Inc Frequently Asked Questions
What is CytomX Therapeutics Inc(STU:6C1)'s stock price today?
The current price of STU:6C1 is €1.04. The 52 week high of STU:6C1 is €4.44 and 52 week low is €0.80.
When is next earnings date of CytomX Therapeutics Inc(STU:6C1)?
The next earnings date of CytomX Therapeutics Inc(STU:6C1) is 2025-03-11 Est..
Does CytomX Therapeutics Inc(STU:6C1) pay dividends? If so, how much?
CytomX Therapeutics Inc(STU:6C1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers